Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study | MicrobiomeTrials
Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study
WITHDRAWNPHASE1INTERVENTIONAL
Trial Details
Start: 2021-05-11Est. Completion: 2022-06-21
Enrollment target: 0 participants
Locations
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Washington University School of Medicine, St Louis, Missouri, United States
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
Seattle Children's Hospital, Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, United States
British Columbia Children's Hospital, Vancouver, British Columbia, Canada
Hospital for Sick Children, Toronto, Ontario, Canada
Other microbiome trials you might be interested in